Joe Y Chang, Professor and Clinical Section Chief at MD Anderson Cancer Center, shared a post on X about a paper he co-authored with colleagues, published in Journal for ImmunoTherapy of Cancer:
“Who needs immunotherapy after SABR for early-stage NSCLC, and who does not?
Our clinical and radiomic AI modeling indicates that only 65% require immunotherapy in this setting.
Biologically guided, individualized immunotherapy is the future.”
Title: Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial
Authors: Maliazurina Saad, Eman Showkatian, Vivek Verma, Qasem Al-Tashi, Muhammad Aminu, Xinyan Xu, Muhamed Qayati Mohamed, Morteza Salehjahromi, Sheeba Sujit, Yuliya Kitsel, Steven Lin, Zhongxing Liao, Saumil Gandhi, David Qian, David Jaffray, Caroline Chung, Natalie Vokes, Jianjun Zhang, Jack Lee, John Heymach, Jia Wu, Joe Chang
You can read the Full Article in Journal for ImmunoTherapy of Cancer.
More posts featuring Joe Y Chang.
